The first instalment of two-part article looking at people behind the most important events and trends in pharma, biotech and wider world of healthcare in 2015.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS